<!doctype html><html lang=en-us><head><meta charset=utf-8><meta name=description content="- A health care provider will be required to administer the drug as a co-pack of two injectable drugs - ViiV Healthcare's cabotegravir and Janssen's rilpivirine will be injected as two separate shots once a month in the bottoms."><meta name=author content="Hettie Henneman"><meta name=generator content="Hugo 0.98.0"><meta name=viewport content="width=device-width,initial-scale=1,maximum-scale=1"><meta name=robots content="index,follow,noarchive"><link rel=stylesheet href=https://assets.cdnweb.info/hugo/base16/css/style.css type=text/css><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Source+Code+Pro:400,700" type=text/css><link rel=alternate href=./index.xml type=application/rss+xml title=NovaBlog><title>HIV treatment gets better as monthly injections set to replace daily pills - NovaBlog</title></head><body><header><div class="container clearfix"><a class=path href=./index.html>[NovaBlog]</a>
<span class=caret># _</span><div class=right></div></div></header><div class=container><main role=main class=article><article class=single itemscope itemtype=http://schema.org/BlogPosting><div class=meta><span class=key>published on</span>
<span class=val><time itemprop=datePublished datetime=2024-04-18>April 18, 2024</time></span>
<span class=key>in</span>
<span class=val><a href=./categories/post>Post</a></span></div><h1 class=headline itemprop=headline>HIV treatment gets better as monthly injections set to replace daily pills</h1><section class=body itemprop=articleBody><p class=align-left><strong>- A health care provider will be required to administer the drug as a co-pack of two injectable drugs</strong></p><p class=align-left><strong>- ViiV Healthcare's cabotegravir and Janssen's rilpivirine will be injected as two separate shots once a month in the bottoms.</strong></p><p class=align-left><strong>- The drug is the first of several long-acting antiretroviral HIV drugs in development</strong></p><p class=align-left><strong>- Researchers hope it will ensure that drugs that can prevent the virus from replicating in their cells are taken consistently by individuals</strong></p><p class=align-left><strong><i>PAY ATTENTION: Join <a href=# rel="nofollow noopener">TUKO.co.ke Telegram</a> channel! Never miss important updates</i></strong></p><p class=align-left>The US Food and Drug Administration has approved a new Human Immunodeficiency Virus (HIV) drug which could see patients stop taking daily antiretroviral therapy drugs.</p><img style=margin:auto;display:block;text-align:center;max-width:100%;height:auto src=https://cdn.statically.io/img/cdn.tuko.co.ke/images/1120/adca84b14889c650.jpeg><p class=align-left>The medicine, known as Cabenuva (cabotegravir and rilpivirine), which is given once a month as an injection, not only frees patients from taking pills on a daily basis but also gives them privacy relative to the current antiretroviral (ARV) regimen.</p><a class=c-article-read-also__image-wrapper href=#><img style=margin:auto;display:block;text-align:center;max-width:100%;height:auto src=https://cdn.statically.io/img/cdn.tuko.co.ke/images/560x315/1b439a51d2ec4008.jpeg></a><a class=c-article-read-also__headline href=# readability=27><p class=c-article-read-also__caption>Read also</p><p class=c-article-read-also__headline-wrapper><span class=c-article-read-also__headline-hover-inner>Kenyans warned to avoid use of bedroom performance enhancement drugs</span></p></a><p class=align-left>Cabenuva has been found to be effective in maintaining a viral suppression among adults living with HIV with no history of treatment failure using 12 jabs only and with no known or suspected resistance to either cabotegravir or rilpivirine, <a href=# rel="nofollow noopener">The Nation reported.</a></p>“Cabenuva reduces the treatment dosing days from 365 days to 12 days per year,” said a statement from Lynn Baxter, head of North America at ViiV Healthcare - the company behind the Cabenuva combination - immediately after the US approval.<p class=align-left>A health care provider administers the drug as a co-pack of two injectable drugs - ViiV Healthcare's cabotegravir and Janssen's rilpivirine - as two separate shots once a month in the behinds.</p><p class=align-left>The drug is the first of several long-acting antiretroviral HIV drugs in development, which researchers hope will ensure that drugs that can prevent the virus from replicating in their cells are taken consistently by individuals.</p><a class=c-article-read-also__image-wrapper href=#><img style=margin:auto;display:block;text-align:center;max-width:100%;height:auto src=https://cdn.statically.io/img/cdn.tuko.co.ke/images/560x315/344141b7eddef3e6.jpeg></a><a class=c-article-read-also__headline href=# readability=28><p class=c-article-read-also__caption>Read also</p><p class=c-article-read-also__headline-wrapper><span class=c-article-read-also__headline-hover-inner>Brave police dog receives standing ovation, welcomed like a hero after he was shot on duty</span></p></a><p class=align-left><strong>PAY ATTENTION: Help us change more lives, join TUKO.co.ke's <a href=# rel="nofollow noopener">Patreon programme</a></strong></p><p class=align-left>Skipped doses put people with HIV at risk, as well as their sexual partners.</p><p class=align-left>The drug's green light is based on the ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) phase III studies involving over 1,100 patients in 16 countries.</p><p class=align-left>Before starting treatment with Cabenuva, oral doses of cabotegravir and rilpivirine (lead-in) were administered to the participants for approximately one month to assess the tolerability of each treatment.</p>“It [approval] signals progress in the response to HIV. It means scientists are working and maybe tomorrow, there will be a cure," said Nelson Otwoma, executive director, national empowerment network of people living with HIV/AIDS.<p class=align-left><strong>PAY ATTENTION: <a href=#>Click 'See First' under 'Follow' Tab to see Tuko.co.ke news on your FB Feed</a></strong></p>"Long-acting injectable will help reduce the burden of daily oral pills and improve adherence,” he added.<a class=c-article-read-also__image-wrapper href=#><img style=margin:auto;display:block;text-align:center;max-width:100%;height:auto src=https://cdn.statically.io/img/cdn.tuko.co.ke/images/560x315/2fd95be3ac2e99e5.jpeg></a><a class=c-article-read-also__headline href=# readability=28><p class=c-article-read-also__caption>Read also</p><p class=c-article-read-also__headline-wrapper><span class=c-article-read-also__headline-hover-inner>Magoha bans hand sanitisers in schools, says students are using them to start fires</span></p></a><p class=align-left>However, among the good news, is the prohibitive cost of the drug that will cost KSh 400,000 a month or more than KSh 4.8 million a year which Viiv argued is 'within the range' of US HIV treatment pills.</p><p class=align-left>A full dose of ARVs for one year costs about KSh 20,000 in Kenya, which relies mostly on generic medicines.</p><p class=align-left><strong><i>Do you have a groundbreaking story you would like us to publish? Please reach us through news@tuko.co.ke or WhatsApp: 0732482690. Contact Tuko.co.ke instantly</i></strong></p><p>Source: TUKO.co.ke</p><p class=postsid style=color:rgba(255,0,0,0)>ncG1vNJzZmivp6x7tcHKqGWcp16gsnCAj2lwcnFdnba3edOrnJqsnZq7tXnMqKWtoJyueqq6yZ6araGfo8Buv8StZKudoKGupLGMnZiipKlivaq4y6xloaydoQ%3D%3D</p></section></article></main></div><footer><div class=container><span class=copyright>&copy; 2024 NovaBlog - <a rel=license href=http://creativecommons.org/licenses/by/4.0/>CC BY 4.0</a></span></div></footer><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://iklan.listspress.com/banner.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://iklan.listspress.com/tracking_server_1.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script>var _paq=window._paq=window._paq||[];_paq.push(["trackPageView"]),_paq.push(["enableLinkTracking"]),function(){e="//analytics.cdnweb.info/",_paq.push(["setTrackerUrl",e+"matomo.php"]),_paq.push(["setSiteId","1"]);var e,n=document,t=n.createElement("script"),s=n.getElementsByTagName("script")[0];t.async=!0,t.src=e+"matomo.js",s.parentNode.insertBefore(t,s)}()</script></body></html>